Cabio Biotech (Wuhan) Co., Ltd. (SHA:688089)
China · Delayed Price · Currency is CNY 19.46
+1.00 (5.42%)
At close: Mar 6, 2026
Cabio Biotech (Wuhan) Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 574.88 | 542.29 | 435.39 | 402.08 | 350.76 |
Other Revenue | - | 13.31 | 8.41 | 31.35 | 0.35 |
| 574.88 | 555.59 | 443.8 | 433.42 | 351.11 | |
Revenue Growth (YoY) | 3.47% | 25.19% | 2.40% | 23.44% | 8.55% |
Cost of Revenue | - | 326.81 | 264.51 | 257.14 | 172.33 |
Gross Profit | 574.88 | 228.78 | 179.29 | 176.29 | 178.78 |
Selling, General & Admin | - | 72.35 | 56.34 | 64.32 | 42.18 |
Research & Development | - | 47.57 | 38.23 | 31.84 | 30.54 |
Other Operating Expenses | 409.91 | 5.36 | 6.38 | 4.56 | 5.01 |
Operating Expenses | 409.91 | 125.82 | 103.21 | 111.93 | 77.08 |
Operating Income | 164.97 | 102.97 | 76.08 | 64.35 | 101.7 |
Interest Expense | - | -0.4 | -0.6 | -0.37 | -0.35 |
Interest & Investment Income | - | 3.52 | 7.41 | 7.12 | 16.83 |
Currency Exchange Gain (Loss) | - | 2.78 | 1.08 | 11.28 | -2.6 |
Other Non Operating Income (Expenses) | 13.99 | -2.31 | 26.37 | 23.94 | 34.41 |
EBT Excluding Unusual Items | 178.96 | 106.56 | 110.34 | 106.33 | 149.99 |
Gain (Loss) on Sale of Investments | - | 0.27 | -2.64 | -37.8 | 0.99 |
Gain (Loss) on Sale of Assets | - | -0 | 0.05 | 0 | -2.4 |
Asset Writedown | - | -5.21 | -4.13 | -0.69 | - |
Other Unusual Items | - | 38.21 | -3.62 | 10.29 | 3.48 |
Pretax Income | 178.96 | 139.82 | 100 | 78.14 | 152.06 |
Income Tax Expense | 22.26 | 19.69 | 13.63 | 16.56 | 20.77 |
Earnings From Continuing Operations | 156.7 | 120.13 | 86.37 | 61.58 | 131.29 |
Minority Interest in Earnings | - | 4.08 | 5.01 | 2.79 | -2.72 |
Net Income | 156.7 | 124.21 | 91.37 | 64.37 | 128.58 |
Net Income to Common | 156.7 | 124.21 | 91.37 | 64.37 | 128.58 |
Net Income Growth | 26.15% | 35.94% | 41.95% | -49.94% | -1.54% |
Shares Outstanding (Basic) | 167 | 168 | 169 | 169 | 168 |
Shares Outstanding (Diluted) | 167 | 168 | 169 | 169 | 168 |
Shares Change (YoY) | -0.69% | -0.80% | -0.11% | 0.69% | 0.31% |
EPS (Basic) | 0.94 | 0.74 | 0.54 | 0.38 | 0.76 |
EPS (Diluted) | 0.94 | 0.74 | 0.54 | 0.38 | 0.76 |
EPS Growth | 27.03% | 37.04% | 42.10% | -50.28% | -1.84% |
Free Cash Flow | - | -38.55 | -228.79 | -73.07 | -70.14 |
Free Cash Flow Per Share | - | -0.23 | -1.35 | -0.43 | -0.42 |
Dividend Per Share | - | 0.201 | 0.200 | 0.214 | 0.236 |
Dividend Growth | - | 0.47% | -6.67% | -9.08% | - |
Gross Margin | 100.00% | 41.18% | 40.40% | 40.67% | 50.92% |
Operating Margin | 28.70% | 18.53% | 17.14% | 14.85% | 28.97% |
Profit Margin | 27.26% | 22.36% | 20.59% | 14.85% | 36.62% |
Free Cash Flow Margin | - | -6.94% | -51.55% | -16.86% | -19.98% |
EBITDA | 219.23 | 157.22 | 123.14 | 90.4 | 125.02 |
EBITDA Margin | 38.13% | 28.30% | 27.74% | 20.86% | 35.61% |
D&A For EBITDA | 54.25 | 54.25 | 47.06 | 26.04 | 23.32 |
EBIT | 164.97 | 102.97 | 76.08 | 64.35 | 101.7 |
EBIT Margin | 28.70% | 18.53% | 17.14% | 14.85% | 28.97% |
Effective Tax Rate | 12.44% | 14.08% | 13.63% | 21.19% | 13.66% |
Revenue as Reported | - | 555.59 | 443.8 | 433.42 | 351.11 |
Advertising Expenses | - | 6.61 | 5.28 | 2.27 | 1.11 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.